TheTechno Optimist.

Alnylam Pharmaceuticals—Alnylam partners with Inceptive for AI-driven RNAi drug discoveryAmvuttra (vutrisiran)Alnylam Pharmaceuticals—Alnylam reports Q2 2026 revenue of $1.172 billion, with Amvuttra reaching $1.01 billion in quarterly revenueAlnylam Pharmaceuticals—Alnylam unveils 'Alnylam 2030' strategy to expand RNAi beyond rare disease into diabetes, obesity, and neurological disorders

Amvuttra (vutrisiran)

by Alnylam PharmaceuticalsUS

RNAi therapeutic silencing transthyretin for ATTR-CM and hATTR-PN, rare amyloidosis diseases.

DeployStage 4 of 5

$1B+ quarterly revenue. Approved ATTR-CM, hATTR-PN. Nucresiran in Phase 3.

Updated 3 Aug 2026Checked 10 Oct0 updates this week

Milestones

Next · TTR revenue guidance revised to $4.2–$4.5B for FY2026
  1. Amvuttra approved for ATTR-CM by FDAJun 2023Complete.
  2. Amvuttra approved for hATTR-PN by FDANov 2023Complete.
  3. Amvuttra quarterly revenue exceeds $1 billionQ2 2026Complete.
  4. TTR revenue guidance revised to $4.2–$4.5B for FY2026Target Aug 2026Current milestone.

Most important updates

Upcoming

  1. Aug 2026TTR revenue guidance revised to $4.2–$4.5B for FY2026 (next)
  2. 2028Nucresiran Phase 3 readout for hATTR-PN
  3. 2030Nucresiran Phase 3 readout and potential approval for ATTR-CM
Primer